Merck experienced strong upward momentum during the trading session, driven primarily by a wave of bullish research note revisions across major Wall Street institutions. Financial analysts, including teams at Wolfe Research and Argus, raised their price targets on the company while maintaining outperformance and buy ratings. Institutional research highlighted growing confidence in the pharmaceutical giant’s underlying cash flow trajectory, solid earnings execution, and long-term valuation upside, which spurred strong buying interest throughout the session.

A key underlying driver for the renewed market enthusiasm is the milestone trial data from Merck’s high-profile oncology partnership with Moderna. Late-stage trial results from the…